is a topic covered in the 5-Minute Clinical Consult
To view the entire topic, please sign in or purchase a subscription.
Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:
-- The first section of this topic is shown below --
Typically benign, slow-growing tumors that arise from cells in the pituitary gland
- Pituitary adenomas have been identified as the third most frequent intracranial tumor; accounts for 10–25%
- Subtypes (hormonal): prolactinoma (PRL) 25–40%, nonfunctioning pituitary adenomas 30%, somatotroph adenoma (growth hormone [GH]) 15–20%, corticotroph adenoma (adrenocorticotropic hormone [ACTH]) 5–10%, thyrotroph adenoma (thyroid-stimulating hormone [TSH]) <1%, gonadotropinoma (luteinizing hormone/follicle-stimulating hormone [LH/FSH]), mixed (1)[A]
- Defined as microadenoma <10 mm and macroadenoma ≥10 mm
- May secrete hormones and/or cause mass effects
- Predominant age: Age increases incidence.
- Predominant sex: female > male (3:2) for microadenomas (often delayed diagnosis in men)
- Autopsy studies have found microadenomas in 3–27% and macroadenomas in <0.5% of people without any pituitary disorders.
- MRI scans illustrate abnormalities consistent with pituitary adenoma in 1/10 persons.
- Clinically apparent pituitary tumors are seen in 18/100,000 persons.
Etiology and Pathophysiology
- Monoclonal adenohypophysial cell growth
- Hormonal effects of functional microadenomas often prompt diagnosis before mass effect.
- PRL increased by functional prolactinomas or inhibited dopaminergic suppression by stalk effect
- Carney complex
- Familial isolated pituitary adenomas: ~15% have mutations in the aryl hydrocarbon receptor–interacting protein gene (AIP); present at a younger age and are larger in size (2)
- McCune-Albright syndrome
- Multiple endocrine neoplasia type 1 (MEN1)-like phenotype (MEN4): germline mutation in the cyclin-dependent kinase inhibitor 1B (CDKN1B) (2)
Multiple endocrine neoplasias
-- To view the remaining sections of this topic, please sign in or purchase a subscription --